Key Players
Competitive Landscape
Competition in spinocerebellar ataxias remains fragmented across small-molecule developers and RNA-therapy specialists. Regenerative-medicine companies and CNS delivery platforms compete for different subtypes and administration settings. Entry depends on genotype-defined cohorts and delivery systems that do not impose an unsustainable treatment burden.
Capital and development activity have moved in two directions since 2025, into subtype-specific licensing and multinational late-stage studies. Solaxa and Alvogen signed a global SLX-100 license worth up to USD 95 million in February 2026. IntraBio posted a pivotal Phase III CACNA1A study in October 2025 that includes genetically confirmed SCA6. Companies now compete on target specificity, trial design and delivery burden across defined hereditary ataxia subtypes.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Solaxa and Alvogen signed a global SLX-100 license in February 2026 with payments worth up to USD 95 million. | SCA27B developers need commercial infrastructure as registrational evidence approaches filing across global markets. | Subtype-specific assets are moving into global licensing structures during registrational preparation for rare neurological programs. | Development milestones, royalties and regional launch rights define the revenue route for genetically defined adult-onset ataxia. |
| IntraBio posted a pivotal Phase III CACNA1A study in October 2025 that includes SCA6 and ten listed sites. | Genetically confirmed patients need coordinated multinational enrollment for a small CACNA1A population. | Late-stage oral programs are grouping related CACNA1A disorders within one controlled study. | Specialist trial networks and future oral treatment access provide the revenue route if efficacy is established. |
| Neurolixis received FDA orphan designation for befiradol in spinocerebellar ataxia during May 2025. | Early developers need regulatory recognition that supports focused evidence planning for rare SCA populations. | Small-molecule programs remain relevant beside RNA and cell therapies within a modality-diverse field. | Revenue depends on advancing the designated asset into SCA clinical testing and securing a viable development partner. |
Biohaven, Vico, Arrowhead, Sarepta, REPROCELL, Steminent, Evox and Kissei also compete on clinical evidence or delivery readiness, but their dated events are not repeated in this three-row table.
Source: Future Market Insights, Spinocerebellar Ataxias Market and Rare Neurological Disease Treatment Market Reports, 2026-2036.
Biohaven and Solaxa cover small-molecule programs while Vico and Arrowhead-Sarepta cover RNA therapies, and REPROCELL with Steminent add a regulated cell-therapy route.
Who leads the Spinocerebellar Ataxias Market?
No company leads every subtype or modality within the Spinocerebellar Ataxias Market. Among verified RNA programs Vico has an active SCA1 and SCA3 trial, while REPROCELL has a near-regulatory cell-therapy route in Japan.
Which companies have documented regulatory designations or review milestones?
REPROCELL holds a Japanese orphan regenerative-medicine designation for Stemchymal and submitted its approval application in June 2026. Neurolixis holds FDA orphan designation for befiradol, while Biohaven completed an FDA review that ended with a complete response letter.
Which companies provide genotype-targeted programs?
Vico targets pathogenic CAG repeats across SCA1 and SCA3, while Arrowhead and Sarepta target ATXN2 in SCA2. Evox is developing an earlier ATXN2 gene-editing program, and IntraBio's pivotal CACNA1A study includes SCA6.
Which suppliers serve the United States and Europe?
Vico is expanding from European trial sites into the United States following FDA IND clearance. Arrowhead and Sarepta hold worldwide development rights, while Solaxa granted global SLX-100 rights to Alvogen for SCA27B.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Biohaven Ltd. | United States and Europe | Oral troriluzole with expanded access remaining available following the November 2025 FDA complete response letter. |
| Vico Therapeutics B.V. | Europe with United States expansion | Intrathecal VO659 for SCA1 and SCA3 with twice-annual dosing and United States IND clearance in February 2026. |
| Arrowhead Pharmaceuticals, Inc. | United States and New Zealand | ARO-ATXN2 RNA interference for SCA2 with clinical supply manufacturing assigned under the Sarepta agreement. |
| Sarepta Therapeutics, Inc. | Worldwide development rights | Licensed clinical ARO-ATXN2 and preclinical SCA1 and SCA3 RNA programs with development and commercialization rights. |
| REPROCELL Inc. | Japan and international partners | Japanese commercialization and distribution rights for Stemchymal with an approval application submitted in June 2026. |
| Steminent Biotherapeutics Inc. | Taiwan and Japan | Manufacturer and original developer of Stemchymal for SCA3 and SCA6 under the Japanese regulatory route. |
| Evox Therapeutics Ltd. | United Kingdom | Preclinical exosome-delivered gene editing that targets ATXN2 for SCA2 and related neurological disease. |
| Neurolixis Inc. | United States and Europe | Befiradol for spinocerebellar ataxia with FDA orphan designation granted in May 2025. |
| Solaxa Inc. and Alvogen | United States and worldwide rights | SLX-100 for SCA27B under a global license worth up to USD 95 million in February 2026. |
| IntraBio Inc. | United States and Europe | Pivotal oral N-acetyl-L-leucine program for CACNA1A disorders that includes genetically confirmed SCA6. |
| Kissei Pharmaceutical Co., Ltd. | Japan | Rovatirelin in additional Phase III testing for broader spinocerebellar degeneration and therefore adjacent to strict hereditary SCA scope. |
Research Methodology
The companies in this section explain market structure and do not form a ranking. A company appears only when current evidence links it to an SCA subtype or a closely related spinocerebellar-degeneration program. Evidence includes regulatory records, trial registries, company filings and dated corporate announcements. Regulatory designations belong to the named sponsor or product while manufacturing roles belong to the entity identified in the source. The 27.0% SCA3 figure remains an FMI estimate for 2026.
